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A broad spectrum detection platform that provides sequence level resolution of target regions would have a significant impact
in public health, case management, and means of expanding our understanding of the etiology of diseases. A previously
developed respiratory pathogen microarray (RPM v.1) demonstrated the capability of this platform for this purpose. This newly
developed RPM v.1 was used to analyze 424 well-characterized nasal wash specimens from patients presenting with febrile
respiratory illness in the Washington, D. C. metropolitan region. For each specimen, the RPM v.1 results were compared against
composite reference assay (viral and bacterial culture and, where appropriate, RT-PCR/PCR) results. Across this panel, the RPM
assay showed $98% overall agreement for all the organisms detected compared with reference methods. Additionally, the
RPM v.1 results provide sequence information which allowed phylogenetic classification of circulating influenza A viruses in
,250 clinical specimens, and allowed monitoring the genetic variation as well as antigenic variability prediction. Multiple
pathogens (2–4) were detected in 58 specimens (13.7%) with notably increased abundances of respiratory colonizers (esp. S.
pneumoniae) during viral infection. This first-ever comparison of a broad-spectrum viral and bacterial identification
technology of this type against a large battery of conventional ‘‘gold standard’’ assays confirms the utility of the approach for
both medical surveillance and investigations of complex etiologies of illness caused by respiratory co-infections.
Citation: Lin B, Malanoski AP, Wang Z, Blaney KM, Ligler AG, et al (2007) Application of Broad-Spectrum, Sequence-Based Pathogen Identification in
an Urban Population. PLoS ONE 2(5): e419. doi:10.1371/journal.pone.0000419
INTRODUCTION
Emerging infections with nonspecific symptoms have enormous
impact on public health and global economics (e.g. severe acute
respiratory syndrome outbreaks, and avian (H5N1) influenza). Such
outbreaks emphasize the need for efficient simultaneous detection of
multiple organisms that will facilitate timely and judicious
implementation of countermeasures for outbreak containment,
treatment interventions, and case management [1]. Ideally, a system
capable of detecting all potentially relevant organisms is needed.
There are many technologies being developed with a view toward
addressing this issue, for example MasscodeTM multiplex RT-PCR
system [2], electrospray ionization mass spectrometry analysis of
PCR amplicons [3], LuminexH xMAP
TM [4], and other microarray
based approaches [5,6,7,8,9,10,11]. While promising, these tech-
nologies have only been tested for detection of a few pathogens or
particular classes of pathogens simultaneously. In addition, these
technologies provide a very limited range of genetic resolution and
require additional testing for determination of detailed mutation or
strain-variations in detected pathogens. High density resequencing
arrays provide resolution of individual nucleotides in long target
sequences (hundreds to thousands of nucleotides) [12,13]. We have
demonstrated discrimination of mutations in targeted pathogens as
well as sensitivities and specificities that are similar to or improved
over those of other technologies based on a subset of the organisms
the microarray is designed to detect. The respiratory pathogen
microarray version 1 (RPM v.1), while not providing comprehensive
coverage of all potential causes of respiratory illness, targets a much
broader range of organisms (including bacteria and DNA and RNA
viruses) in a single test than other potential methods [14,15,16,17].
Our previous work on the RPM v.1 demonstrated detection of
pathogens individually at 10
1–10
3 genome copies using spiked
samples as well as select organisms in clinical samples. We have
also demonstrated the use of culture isolates of clinical samples in
which a more detailed analysis of strain distribution in influenza
viruses was possible [17]. Unfortunately, when directly using
clinical samples, only the successful attribution of flu samples to the
correct flu season was accomplished [15]. The accuracy of the
base calls from the array has been compared with only de novo
sequencing using culture isolates of clinical samples. Our studies
demonstrate that one of the challenges in developing multiplex
detection systems for a broad range of very different organisms is
the validation of the test results. Few samples are available that
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pathogens. Similarly, the archived clinical specimens used in our
previous studies were originally only tested for a few select targets.
When multiple organisms were detected by the RPM v.1, it was
not always possible to perform confirmatory testing due to a lack of
available materials. This is a limitation of using archived samples
for validating newly developed multiplex assays as it is very time-
consuming and costly thus making multiple confirmatory assays in
clinical specimens very difficult to achieve.
In this study, we validate the potential of the respiratory
pathogen microarray (RPM v.1) for providing broad-spectrum
pathogen detection. A set of 424 clinical samples collected in the
Washington, DC metropolitan region from December 2004 to
February 2005 were subjected to a full panel of conventional
microbial analysis (culture and/or RT-PCR/PCR) as well as
analysis by the RPM v.1 microarray. This set of samples
demonstrated good agreement across the panel of tests making
authentication of multiple detection events by the RPM v.1
microarray possible. Many specimens from this set represented co-
infections providing a range of multi-target samples for analysis.
Here we use clinical samples rather than culture isolates and
demonstrate detailed analysis of strain distributions of influenza
viruses within a flu season as well as providing a phylogenetic
measure of circulating influenza strains. The accuracy of the base
calls was confirmed by comparison to de novo sequencing using
representative clinical samples. This comparison of a broad-
spectrum viral and bacterial identification technology with a large
battery of conventional ‘‘gold standard’’ assays represents more
rigorous testing of our approach for both medical surveillance and
investigation of complex etiologies than has been carried out
previously. This study provides a previously unavailable funda-
mental assessment of a multiple pathogen detection assay and
paves the way to improvements for a microarray-based platform
which would provide more comprehensive multiple pathogen
detection in a single test. The implications and limitations of the
assay are also discussed.
METHODS
Specimen collection and processing
Specimens were collected at six military treatment facilities in the
Washington, DC metropolitan region between December 2004
and February 2005. The demographics of the Washington, DC
metropolitan region have previously been shown to have a broad
age, gender, and geographic distribution [18]. Patients were
recruited from both emergency department and clinic settings,
after the nature and possible consequences of the study were
explained and informed consents were obtained from participants.
Patient samples were stored in CVM media (Hardy Diagnostics,
Santa Maria, CA) for viral culture processing, or stored in tryptic
soy broth with glycerol for bacterial analysis, and were shipped
frozen to destination laboratories for analysis. These samples were
collected, and this research has been conducted in compliance
with all applicable federal and international regulations governing
the protection of human subjects in research, under Naval Medical
Center protocols #B05LHOOOOO-018.
Microarray hybridization and analysis
The RPM v.1 design and specimen process protocols for
microarray analysis were described in detail in previous publica-
tions [14,15,16,17]. Microarray hybridization and processing were
carried out according to the manufacturer’s recommended
protocol (Affymetrix Inc., Santa Clara, CA) with the following
modifications: Purified PCR products were fragmented at 37uC
for 5 minutes, and then labeled with Biotin-N6-ddATP at 37uC
for 30 minutes. Hybridization was carried out in the hybridization
oven at 45uC and 60 rev/min for 4 hours. The image scanning
and processing to produce FASTA output file were performed as
previously described [16]. Final pathogen identification for the
RPM v.1 assay was performed using Computer-Implemented
Biological Sequence Identifier (CIBSI) Version 2.0 software [19],
an automatic pathogen identification algorithm (based on nucleic
acid sequence) that was developed and tested in detail in previous
studies [16,20].
Reference assays
Independent assays were performed using bacterial and viral
culture except for difficult-to-culture pathogens, for which PCR
methods were used. Additional assays, primarily conventional
and/or real-time PCR and RT/PCR, were performed on culture
negative samples to test for pathogens occurring at titers too low
for culture and/or loss of viability from transportation. Overall,
a specimen was defined as ‘‘positive’’ for a pathogen if the com-
posite assay results (culture and/or duplicate PCR assays) were
positive.
Viral analyses were performed by FOCUS Diagnostics, Inc.,
a CAP-certified reference laboratory (Cypress, CA) or by Air
Force Institute for Operational Health (Brooks City Base, TX).
Viral processing included: inoculation of sample, monitoring for
cytopathic effect (7–15 days of monitoring), sub-passage as
necessary and confirmatory testing as needed (i.e., direct mono-
clonal immunofluorescence assay, indirect immunofluorescence
assay or PCR).
Bacterial analyses were performed at the Naval Health
Research Center (NHRC, San Diego, CA) Respiratory Disease
Laboratory. Samples were then analyzed for the presence of
bacterial pathogens utilizing classic culture techniques with
selective agar plates. For all culture methods, if growth resembled
colonies appropriate to a targeted pathogen, confirmatory tests
(e.g., susceptibility disks, biochemical testing) were conducted to
verify the identity of the suspected colony.
Initial PCR analyses of difficult-to-culture pathogens (Bordetella
pertussis, Chlamydia pneumoniae/psittaci, coronavirus OC43 and 229E,
and Mycoplasma pneumoniae) were performed at the NHRC
Respiratory Disease Laboratory or FOCUS Diagnostics, Inc.
(Cypress, CA). Further species-specific RT/PCR amplification
assays were performed on culture-negative but RPM v.1-positive
samples with positive (culture-positive, RPM v.1-positive) and
negative (culture-negative, RPM v.1-negative) controls. These
assays were performed at NRL using previously published primers
(Table S1). In general, 25 ml PCR reactions were run on MyiQ
TM
real-time PCR detection systems (Bio-Rad, Hercules, CA, USA).
Conventional PCR assays were analyzed by electrophoresis
thorugh1.5% TAE agarose gels. Sequencing reactions were
performed by SequeTech (Mountain View, CA).
Sequence alignments for influenza-positive samples were per-
formed on HA3 hemagglutinin sequences using MagAlign function of
Lasergene version 6 (DNASTAR, Inc. Madison, WI). Rooted
phylogenetic trees were generated by using neighbor-joining
method in PAUP* 4.0 (Sinauer Associates, Inc., Publishers,
Sunderland, MA) and rooted to A/Panama/2007/99. Reliability
estimates were assessed using 1,000 bootstrap replicates.
RESULTS
A total of 424 samples were tested using RPM v.1 assays and
parallel reference assays (culture and/or PCR tests). The sensitivity
and specificity of the RPM v.1 assay were determined using
Multiple Pathogen Detection
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[15]. Table 1 shows the collective number of positive results
obtained using culture assays only, all reference assays, and RPM
v.1. Of the 424 samples, 269 (63.4%) were identified as positive for
influenza A by RPM v.1, compared to 176 (41.5%) by culture (30
to 42-day). Similarly, 46 (10.8%) were positive for influenza B
using RPM v.1, while culture identified 28 (6.6%) as influenza B-
positive. RPM v.1 identified 24 (5.6%) as positive for coronavirus
(229E or OC43), while PCR identified 28 (6.6%) samples as
coronavirus (229E and OC43) positive. Additional pathogens were
identified in low incidence–shown here as [RPM v.1 vs. culture],
including adenovirus-[9 (2.1%) vs. 2 (0.5%)], Streptococcus pneumo-
niae-[38 (8.9%) vs. 8 (1.9%)], and S. pyogenes-[13 (3.1%) vs. 9
(2.1%)]. RPM v.1 also identified type I and III parainfluenza (PIV)
virus, PIV1 (1, 0.2%), PIV3 (2, 0.5%), rhinovirus type 89 (2, 0.5%),
M. pneumoniae (3, 0.7%), and Neisseria meningitides (14, 3.3%) which
were not identified by culture. The RPM v.1 did not contain
resequencing tiles for PIV2 or Haemophilus influenzae, both of which
were detected by culture, PIV2 (2, 0.5%) and H. influenzae (7;
1.7%).
In this study, influenza virus was the most commonly identified
respiratory pathogen by all methods. With respect to all reference
assays, the RPM v.1 method showed a detection sensitivity of 99%
and a specificity of 96%, and an overall agreement of 98%
(Table 2) for influenza A virus. For influenza B, the RPM v.1
detection sensitivity and specificity were 98% with an overall
agreement of 97% (Table 2). All but three influenza culture-
positive specimens were also positive on microarrays. However,
two specimens identified as influenza A-positive by culture were
clearly detected as influenza B on microarrays. Real-time RT-
PCR later concurred with the microarray results and not culture
that these 2 specimens were indeed influenza B-positive. The
RPM v.1 also demonstrated excellent detection sensitivity,
specificity, and overall agreement with respect to the reference
assay results for other pathogens detected (Table S2–S3).
The capability of the RPM v.1 system for the identification of
complex mixtures of pathogens [15,16,17] were further demon-
strated through assessment of the incidence of co-infections in the
424 samples. Of these samples, 58 (13.7%) showed viral or viral/
bacterial co-infections as determined by RPM and/or culture
(Table 4). These co-infections were further verified using published
type-specific PCR assays and in-house specific PCR primers
(Table S1). It is well known that S. pneumoniae and N. meningitidis
colonize the mouth and upper respiratory system, so it is not
surprising that these were common co-infections found in clinical
samples. However, consistent with our previous study [15],
quantitative real-time PCR data showed that most of the S.
pneumoniae present in influenza-positive samples harbored a high
titer ($10
4 genome copies/ml) as compared to influenza-negative
samples (data not shown). The high titer bacteria present in these
clinical samples was possibly virally induced bacterial superinfec-
tion, as first suggested by the findings of Madhi et al. [21] and
Peltola and McCullers [22].
A critical aspect for influenza epidemiology is to track genetic
changes within influenza strains, since antigenic drift is the
mechanism by which influenza viruses escape from immunological
pressure induced by previous natural exposures and vaccinations.
Analysis of the key amino acids (deduced from nucleotide
sequence) in the HA3 sequences of all influenza A H3N2 positive
isolates revealed two major circulating strains: A/New York/258/
2005 (Group I) and A/Aichi/133/2005 (Group II) (Table 3).
Group I belongs to the A/California/7/2004 lineage and carries
signature amino acids substitutions in antigenic site D: valine to
isoleucine at position 226 (V226I) and serine to proline at position
227 (S227P). Group II showed an A/Wellington/1/04 lineage
signature amino acid substitution at position 227 (S227P), and
serine to asparagine at position 216 (S216N), the key amino acid at
antigenic site B. Surprisingly, the only outlier sample was identified
as A/Wyoming/3/03 (with IS)-like isolate. Amino acids position at
216 correspond to 188, 226 corresponds to 198, and 227
corresponds to 199 on the tiled prototype sequence (Table 3).
Using 15 representative samples, phylogenetic analysis compar-
ison between the sequences generated from RPM v.1 (68 to 96%
resolved bases) (Fig. 1A) and the sequences generated via
conventional sequencing (100% resolved bases) (Fig. 1B), showed
similar results, indicating that ambiguous base calls from the
microarray did not affect phylogeny determination for influenza A
viruses (Table 3, Fig. 1). The representative samples were the A/
Wyoming/3/03 (with IS)-like isolate and 14 other samples
randomly selected from the two groups. The resulting phyloge-
netic trees clearly confirmed that the influenza A/H3N2 positive
samples consisted of two major groups: A/New York/258/2005
(A/California/7/2004 lineage) and A/Aichi/133/2005 (A/Wel-
lington/1/04 lineage) with one A/Wyoming/3/03 (with IS)-like
isolate as an outlier. Further confirmation using all HA3 sequences
produced the same groups that were identified by tracking key
amino acid substitutions (data not shown). Both groups apparently
originated from the common ancestor A/Fujian/411/2002
Table 1. Pathogens identified for 424 matched specimens-
overall microarray vs. reference methods.
......................................................................
Organism
Culture
(+)
Ref

(+)
RPM
v.1 (+)
Ref
 (+),
RPM
v.1 (2)
Ref
 (2),
RPM
v.1 (+)
Adenovirus 2 8 9 0 1
Coronavirus 28* 29 24 6 2
Influenza A 176 263 269 1 7
Influenza B 28 41 46 1 6
PIV 1 0 0 1 0 1
PIV3 0 0 2 0 2
Rhinovirus 0 1 2 1 1
M. pneumoniae 02 3 0 1
S. pneumoniae 84 0 3 8 3 1
S. pyogenes 91 3 1 3 0 0
Negative 176 52 59 0 7
Note: *Coronaviruses were identified through CAP-certified PCR method, Ref
:
reference assays-culture and/or RT-PCR/PCR positive.
doi:10.1371/journal.pone.0000419.t001
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Table 2. Evaluation of the detection efficiency for influenza A
and B viruses in clinical samples
......................................................................
Influenza A Influenza B
Ref
+ Ref
2 Ref
+ Ref
2
RPM v.1+ 262 7 40 6
RPM v.12 2 153 1 377
Sensitivity 99% 98%
Specificity 96% 98%
Overall agreement 98% 98%
Ref
: reference assays-culture and/or PCR
doi:10.1371/journal.pone.0000419.t002
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York-like strains suggesting that Wellington-like strains had more
genetic variations and they might be evolved from California
lineage. For influenza B, the results showed that all the isolates
were close to the B/Texas/3/2002 strain, which belongs to
B/Yamagata/16/88 lineage and was the circulating strain from
the 2004–2005 influenza season.
DISCUSSION
Despite the effort to establish completely blind independent testing
for every pathogen (viral and bacterial culture and, where appro-
priate, RT-PCR/PCR), differences in detection sensitivities of the
methods and transportation issues necessitates using further
confirmatory testing. This is because a measure of uncertainty is
introduced in the quality of the reference assays as the services of
a local reference laboratory could not be arranged (samples were
transported to San Diego, CA). Furthermore, although large
sample volumes are set aside for reference assays, a reduction in
detection sensitivity is still inevitable because these samples are
split and frozen before testing for each viral and bacterial agent in
separate cultures. To reduce this uncertainty, archived samples
stored at the time of the original testing are retested using real-time
RT-PCR/PCR in house as an additional reference method on
RPM-positive but culture-negative samples, using positive (positive
for both RPM and culture) and negative controls (negative for
both RPM and culture). Combining the results of all confirmatory
tests demonstrates an excellent concordance with RPM v.1
(Table 2 and Table S2–S3) with $98% overall agreement for all
the organisms detected. The false positive/negative rate is within
a reasonable range expected when testing any two methods such as
is seen when PCR assay methods are compared to culture methods
for all but two of the organisms. The detection sensitivity for
Coronaviruses and S. pneumoniae by RPM v.1 is lower compared to
Table 3. Nucleotides difference in hemagglutinin (HA3) genes identified by RPM v.1 from 250 influenza A/H3N2 isolates.
..................................................................................................................................................
Position aa/nt* Amino acid and nucleotide substitution
&
A/Fujian/411/02
# A/Wyoming/3/03 A/Wellington/1/04 A/California/7/04
8 (36)/25 Val/GTT Val/GTT 1 Val/GTC 71 Val/GTT 166
28 (56)/83 His/CAT His/CAT 1 His/CAT 56 His/CAT 166
Tyr/TAT 15
39 (67)/116 Ile/ATA Val/GTA 1 Ile/ATA 71 Ile/ATA 167
81(109)/244 Arg/AGG Arg/AGG 1 Arg/AGA 64 Arg/AGG 161
Arg/AGG 3
100 (128)/299 Ala/GCT Thr/ACT 0 Thr/ACT 33 Thr/ACT 90
117 (145)/352 Lys/AAA Asn/AAC1 Asn/AAC6 2 Asn/AAC1 4 4
131 (159)/393 Tyr/TAC Phe/TTC 1 Phe/TTC 65 Phe/TTC 159
149 (177)/446 Leu/TTG Leu/TTG 1 Leu/CTG 39 Leu/TTG 144
161 (189)/483 Ser/AGT Asn/AAT 1 Asn/AAT 67 Asn/AAT 152
188 (216)/564 Asn/AAT Asn/AAT 1 Ser/AGT 67 Asn/AAT 144
Ser/AGT 1
195 (223)/584 Val/GTA Val/GTA 1 Ile/ATA 59 Val/GTA 160
198 (226)/593 Val/GTC Ile/ATC 1 Val/GTC 61 Ile/ATC 43
199 (227)/596 Ser/TCC Ser/TCC 1 Pro/CCC 66 Pro/CCC 5
Note: * Amino acid (aa) and nucleotide (nt) positions correspond to the ‘‘prototype sequence’’ for hemagglutinin of influenza A/H3N2 (HA3) on RPM v.1; the number in
the parenthesis correspond to the position of full length HA3 sequence,
& amino acid and its corresponding codon at each position were separated by ‘‘/’’. SNPs relative
to the prototype sequence are underlined. The numbers in column 4, 6, and 8 indicate the number of samples containing the amino acid substitution;
#HA3 prototype
sequence was derived from A/Fujian/411/02 strain. A/New York/258/2005 (California-lineage) and A/Aichi/133/2005 (Wellington-lineage) represent two major groups
identified from all isolates. The one outlier was identified as A/Wyoming/3/03 (with IS)-like isolate.
doi:10.1371/journal.pone.0000419.t003
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Table 4. Comparative results for specimens positive for
multiple pathogens.
......................................................................
Organism Culture (+) RPM v.1 (+)
Adenovirus+Influenza A N.C. 3
Coronavirus+Influenza A 4* 8
Coronavirus+N. meningitides -1
Influenza A+Influenza B N.C. 3
Influenza+PIV N.C. 1
Influenza A+H. Influenzae 2 N.C.
Influenza A+M. pneumoniae N.C. 1
Influenza A+N. meningitides N.C. 7
Influenza A+S. pneumoniae 11 5
Influenza B+Adenovirus N.C. 1
Influenza B+Coronavirus N.C. 1
Influenza B+S. pneumoniae N.C. 5
Influenza B+S. pyogenes N.C. 3
N. meningitides+S. pneumoniae N.C. 2
Influenza A+N. meningitides+S. pneumoniae N.C. 2
Influenza A+Neisseria spp.+S. pneumoniae N.C. 1
Influenza B+Neisseria spp.+S. pneumoniae N.C. 1
Influenza A+Influenza B+S. pneumoniae N.C. 1
Influenza A+Influenza B+Coronavirus+S.
pneumoniae
N.C. 1
Rhinovirus+PIV+N. meningitides+S. pneumoniae N.C. 1
Note: *Coronaviruses were identified through CAP-certified PCR method, N.C.:
no coinfection found, samples may have identified as positive for one of the
organisms
doi:10.1371/journal.pone.0000419.t004
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optimize the primers sets used in the RPM v.1 assay for these
organisms. However, the specificity remains very high for all
organisms.
The ability to test for multiple pathogens is increasingly recogn-
ized as a necessity, especially in cases where differential diagnosis
of etiological agents is difficult. Broad-spectrum diagnostics are
particularly useful when different etiological agents that cause
similar symptoms (such as respiratory illness) co-circulate in the
same populations, or when co-infections of multiple organisms are
of potential importance to epidemiology, symptomology, or
treatment. However, it is difficult, cumbersome and costly to
detect multiple pathogens and co-infections using culture methods
or single test PCR methods. Currently, the reported coinfection
rate among respiratory pathogens varies (4.5–23%) due to the
different breadth and sensitivities of the detection methods [23].
Using RPM v.1 (and confirmed by real-time RT-PCR/PCR), this
study found that 58 (13.7%) of the tested samples showed viral or
viral/bacterial co-infections (Table 4). It is a challenge that will
only increase in difficulty as more organisms are covered to
establish the validity of any broad spectrum platform against
‘‘gold’’ standards as few existing archive samples have been tested
for such a large number of organisms.
In addition to pathogen detection, sequences obtained using the
RPM v.1 provide useful additional information for tracking strain
variation without additional testing. This study shows that the
majority of the clinical samples tested are positive for influenza A/
B virus (74%), which is not surprising for the samples collected
during the flu season. Comparison of conventional sequencing for
representative influenza A positive samples demonstrates the utility
of this information from RPM v.1. The isolates belong to two
major lineages of influenza A/H3N2 and all isolates are evolved
from the A/Fujian/411/02 strain, one component of the influenza
vaccine for 2004–2005 season. Antigenic drift selected by
vaccination apparently leads to new strains of influenza A/
H3N2 during 2004–2005. As anticipated, the RPM v.1 identifies
the A/California/7/2004 lineage as the dominant circulating
strain. The interesting feature is the emergence of Wellington
lineage strains at the same time in significant numbers, which are
of the same clade as the A/Wisconsin/67/2005 strain, a suggested
Figure 1. Rooted phylogenetic analysis of the hemagglutinin (HA3) genes of 15 representative influenza A/H3N2 isolates and reference strains.
(A) phylogenetic tree generated using sequences obtained from RPM v.1, (B) phylogenetic tree generated using de novo sequences from the same
set of the isolates. Reference sequences were obtained from GenBank and indicated in underlined, bold font. Numbers above branches indicate
bootstrap values from 1000 replicates. Note: ***-the A/Wyoming/3/03 (with IS)-like isolate. Bootstrap values above 50% were shown at branches.
Scale near the bottom of each panel relates the length of a branch to the number of nucleic acid substitutions.
doi:10.1371/journal.pone.0000419.g001
Multiple Pathogen Detection
PLoS ONE | www.plosone.org 5 May 2007 | Issue 5 | e419vaccine component for 2006–2007 season. These results confirm
that the RPM v.1 is a useful tool itself not only for influenza
surveillance but also for predicting antigenic variation that will be
beneficial for vaccine candidate predication. Considering all of
these results, a high level of confidence in the general reliability of
the resequencing approach for simultaneous pathogen detection
and strain/variant identification directly from clinical samples has
been established.
The results show excellent correlation with reference assays, but
neither the RPM v.1 nor the tests conducted in the reference
assays represent complete coverage of all respiratory pathogens.
Consequently, no pathogen is detected for 14% of the specimens,
but the patients still exhibit flu-like symptoms. Furthermore, the
RPM v.1 is designed as a proof-of-concept microarray for the
detection of more than 20 common respiratory pathogens
encountered among military basic trainees with large section of
the chip dedicated to adenoviruses and influenza viruses, but in
this work it is used for surveying a slightly different population
within Washington, D.C. metropolitan region, which have a broad
age, gender, and geographic distribution and may have a different
mix of common pathogens. In addition, the major causes of the
common cold, rhinoviruses and enteroviruses, are under repre-
sented on the RPM v.1. Subsequently, only a few strains of the
recognized 99 strains of rhinovirus and none of the enteroviruses
can be detected by RPM v.1. The confirmatory assays do identify
several organisms (i.e. PIV2, H. influenzae) in clinical specimens
that the RPM v.1 is not designed to detect. Additionally,
preliminary testing of a new chip design with more thorough
coverage (.75 pathogens) identifies pathogens that the confirma-
tory assays detect but which the RPM v.1 cannot detect
(unpublished data). This indicates the potential of this technology
to reduce the number of samples not attributed to a tested
organism to a significantly smaller number than is currently
possible.
The major difficulties of the current technology are associated
with the primer selection for amplification of the chosen targets.
The design of the multiplex amplification strategy is a time
consuming effort. The current system remains somewhat vulner-
able to the rapid mutation of RNA viruses and each new
resequencing array design that increases the number of pathogens
would require recalibrating the multiplex primers mix. One
solution that already mitigates this is the grouping of pathogens
into subsets for amplifications that are recombined for chip
analysis. In the future, the more variable pathogens can be
partitioned into their own mix so that the performance for the
conserved pathogens i.e. bacteria are not affected when primers
are changed and only mixes that have targets added to them
require recalibration. Simplified redesign and alternative amplifi-
cation methods that provide the necessary sensitivity with more
comprehensive coverage are also currently being investigated.
Despite these limitations, the positive results of this study lead us to
believe the resequencing microarray is an excellent candidate for
the next generation pathogen detection tools and provide
a modern, broad-spectrum infectious disease surveillance solution
for critical decision makers, including healthcare providers,
patients, public health authorities, and framers of biosecurity
policy.
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